相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。International Consensus Guidelines for the Optimal Use of the Polymyxins Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP)
Brian T. Tsuji et al.
PHARMACOTHERAPY (2019)
Efficacy of tigecycline monotherapy versus combination therapy with other antimicrobials against carbapenem-resistant Acinetobacter baumannii sequence type 2 in Heilongjiang Province
Jiaying Li et al.
ANNALS OF PALLIATIVE MEDICINE (2019)
The Search for a Practical Method for Colistin Susceptibility Testing: Have We Found It by Going Back to the Future?
Michael J. Satlin
JOURNAL OF CLINICAL MICROBIOLOGY (2019)
Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial
Mical Paul et al.
LANCET INFECTIOUS DISEASES (2018)
In vitro activity of colistin mono- and combination therapy against colistin-resistant Acinetobacter baumannii, mechanism of resistance, and clinical outcomes of patients infected with colistin-resistant A. baumannii at a Thai university hospital
Yongyut Lertsrisatit et al.
INFECTION AND DRUG RESISTANCE (2017)
Polymyxins: Antibacterial Activity, Susceptibility Testing, and Resistance Mechanisms Encoded by Plasmids or Chromosomes
Laurent Poirel et al.
CLINICAL MICROBIOLOGY REVIEWS (2017)
Secular trends in Acinetobacter baumannii resistance in respiratory and blood stream specimens in the United States, 2003 to 2012: A survey study
Marya D. Zilberberg et al.
JOURNAL OF HOSPITAL MEDICINE (2016)
Carbapenem Breakpoints for Acinetobacter baumannii Group: Supporting Clinical Outcome Data from Patients with Bacteremia
Yi-Tzu Lee et al.
PLOS ONE (2016)
Colistin-Resistant Acinetobacter baumannii: Beyond Carbapenem Resistance
Zubair A. Qureshi et al.
CLINICAL INFECTIOUS DISEASES (2015)
Meta-analysis of colistin for the treatment of Acinetobacter baumannii infection
Zhijin Chen et al.
SCIENTIFIC REPORTS (2015)
Role of OmpA in the Multidrug Resistance Phenotype of Acinetobacter baumannii
Younes Smani et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
In Vitro Responses of Acinetobacter baumannii to Two- and Three-Drug Combinations following Exposure to Colistin and Doripenem
Louise M. Oleksiuk et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Risk Factors and Outcome Analysis of Acinetobacter baumannii Complex Bacteremia in Critical Patients*
Hao-Yuan Lee et al.
CRITICAL CARE MEDICINE (2014)
Treatment Options for Carbapenem-Resistant and Extensively Drug-Resistant Acinetobacter baumannii Infections
J. Alexander Viehman et al.
DRUGS (2014)
Comparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections
A. Batirel et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2014)
Major Variation in MICs of Tigecycline in Gram-Negative Bacilli as a Function of Testing Method
Dror Marchaim et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2014)
First Report of an OXA-23 Carbapenemase-Producing Acinetobacter baumannii Clinical Isolate Related to Tn2006 in Spain
P. Espinal et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Carbapenem-resistant Acinetobacter baumannii: epidemiology, surveillance and management
Jason M. Pogue et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2013)
Antimicrobial-Resistant Pathogens Associated with Healthcare-Associated Infections: Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010
Dawn M. Sievert et al.
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY (2013)
The Rise of Carbapenem-Resistant Acinetobacter baumannii
Benjamin A. Evans et al.
CURRENT PHARMACEUTICAL DESIGN (2012)
Synergistic Killing of Multidrug-Resistant Pseudomonas aeruginosa at Multiple Inocula by Colistin Combined with Doripenem in an In Vitro Pharmacokinetic/Pharmacodynamic Model
Phillip J. Bergen et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Carbapenems: Past, Present, and Future
Krisztina M. Papp-Wallace et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Activities of colistin- and minocycline-based combinations against extensive drug resistant Acinetobacter baumannii isolates from intensive care unit patients
Wang Liang et al.
BMC INFECTIOUS DISEASES (2011)
Colistin: recent data on pharmacodynamics properties and clinical efficacy in critically ill patients
Argyris S. Michalopoulos et al.
ANNALS OF INTENSIVE CARE (2011)
Carbapenem-resistant OXA-23-producing Acinetobacter baumannii isolates causing ventilator-associated pneumonia
Marcelo Carneiro et al.
AMERICAN JOURNAL OF INFECTION CONTROL (2010)
Treatment of Acinetobacter Infections
Joel Fishbain et al.
CLINICAL INFECTIOUS DISEASES (2010)
Multiresistant Acinetobacter baumannii infections: epidemiology and management
Jose Garnacho-Montero et al.
CURRENT OPINION IN INFECTIOUS DISEASES (2010)
In vitro synergistic activity of tigecycline and colistin against XDR-Acinetobacter baumannii
Murat Dizbay et al.
JOURNAL OF ANTIBIOTICS (2010)
Resistance to Colistin in Acinetobacter baumannii Associated with Mutations in the PmrAB Two-Component System
Mark D. Adams et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii and selection of tigecycline-amikacin synergy
Ellen S. Moland et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Genetic Basis of Multidrug Resistance in Acinetobacter baumannii Clinical Isolates at a Tertiary Medical Center in Pennsylvania
Jennifer M. Adams-Haduch et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, gram-negative bacilli infections: A prospective, open-label, uncontrolled study
Nikolaos Markou et al.
CLINICAL THERAPEUTICS (2008)
CarO, an Acinetobacter baumannii outer membrane protein involved in carbapenem resistance, is essential for L-ornithine uptake
Maria A. Mussi et al.
FEBS LETTERS (2007)
Tigecycline MIC testing by broth dilution requires use of fresh medium or addition of the biocatalytic oxygen-reducing reagent Oxyrase to standardize the test method
PA Bradford et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit
HS Sader et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2005)
Relationship between β-lactamase production, outer membrane protein and penicillin-binding protein profiles on the activity of carbapenems against clinical isolates of Acinetobacter baumannii
F Fernández-Cuenca et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2003)
分享论文
